SCIENCE OF CERTAINTY
Progress your preclinical
with speed and certainty
Q3-2023 Trading statement
Continued strong performance
In Q3-2023, we saw strong growth across many disease areas. The CRO business grew 44% compared to the same quarter last year. We also made strong progress in our Discovery & Partnership business.
Highly Specialized Preclinical Solutions
Explore our industry-leading preclinical NASH model portfolio. Our GAN DIO-NASH mouse model is ranked #1 by the LITMUS consortium for human translatability. Profile your drug candidate in our biopsy-confirmed mouse models of NASH, using clinical endpoints and AI-assisted histological analyses.
We have more than 15 years experience within preclinical obesity studies to help progress your drug candidate. We provide off-the-shelf diet-induced obese (DIO) rodent models for profiling the efficacy and mode of action of your compound on endpoints ranging from food intake over energy expenditure to whole-brain activation signatures.
Progress your drug discovery with Gubra’s broad portfolio of mouse models recapitulating acute and chronic kidney diseases. Our ReninAAV hypertension-accelerated diabetic kidney disease (DKD) mouse is one of the most advanced models available for profiling drug candidates with therapeutic potential in DKD.
Gubra’s unique 3D light sheet imaging platform can visualize drug distribution, map drug targets and quantify therapeutic responses in the intact brain at single cell resolution. Our fully automated light sheet imaging pipeline accommodates up to 100 brains per study with a fast turn-around time of 2.5 months. Get instant access to your imaging data in our interactive atlas-guided 3D brain-viewer.
We provide end-to-end customized studies in our spirometry-confirmed and bleomycin-induced mouse models of idiopathic pulmonary fibrosis (IPF). Accelerate your drug candidate by exploring pivotal lung functional endpoints in combination with AI-assisted histopathological scoring and quantitative histology.
We are experts in preclinical diabetes research, and offer customized studies in canonical rodent models of type 2 and type 1 diabetes to guide development of your anti-diabetic compound. Study data provided by our multidisciplinary teams can inform about efficacy on metabolic and glycemic endpoints as well as whole-pancreas islet and β-cell numbers for interpreting mode of action.
Gubra’s light-sheet microscopy platform allows for 3D imaging of all organs in the mouse and rat. Our fully automated imaging pipeline works seamlessly in combination with our in vivo models and in-house developed AI-driven image analysis to ensure precision-mapping of drug distribution and quantification of histological endpoints.
High-quality histology is essential in preclinical drug development and can inform about drug mode of action. We offer routine and advanced histology services, including core histology, multiplex immunohistochemistry and RNAScope® as well unbiased stereology analysis for best-practice whole-sample quantitative histology.
We offer a full palette of advanced sequencing technologies, including bulk RNAseq, single-nucleus RNAseq, spatial transcriptomics and ATACseq. We accept most types of tissues, including fresh frozen or archival samples (FFPE). Trust Gubra for fast turnaround and expert bioinformatics. Get instant access to your data in GubraView, our interactive data viewer.
target and peptide drug discovery
Discovery & Partnerships
Gubra has a long history of successful peptide drug discovery. Our AI-driven streaMLine platform quickly develops a peptide hit into a clinical ready drug candidate with balanced properties and strong IP protection. We do linear peptides, cyclic peptides, disulfide-rich peptides (DRP), peptide drug-conjugates and more.
Navigate multifactorial diseases and transform your data into target discovery with us. Gubra empowers scientific ingenuity with fitting AI-assisted tools and high-quality data to unveil drug potential. Our pipeline ensures a rapid transition from target identification, target qualification and in vivo target validation.
Gubra is known as a professional and scientific strong collaboration partner, and we have several successful partnerships ongoing. Our agile and data-driven approach to project management is valued by our partners and is key to our success and speed. Partnerships are important to us, and we always look for new collaboration opportunities.
Science with purpose
CRO & Biotech Company
Gubra is specialized in high-end preclinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. The combination of our advanced, high-end models and technologies ensures rapid turnaround time and high quality data.
Workplace full of opportunities
We offer an exciting and challenging work environment, where job satisfaction and personal development are top priorities. Together, we are scientific entrepreneurs. Explore our open positions if you would like to join the Gubra team.
We act responsibly
For further information
Hørsholm Kongevej 11B
+45 3152 2650